Hildred Capital’s Post

Crown Laboratories, Inc. and Revance Announce Entry Into Merger Agreement Under the terms of the agreement, which has been unanimously approved by Revance's Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. "This is a significant step forward in Crown's vision to become a fully integrated global aesthetics and skincare company, bringing innovative solutions to physicians, patients and consumers in the incredibly dynamic aesthetics and skincare market," said Jeff Bedard, founder and Chief Executive Officer of Crown. "Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown's innovative line of skincare products. As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States." Mark Foley, President and Chief Executive Officer of Revance said, "Over the past several years, Revance has brought to the market innovative aesthetic and therapeutic offerings that have elevated patient and physician experiences. We are excited about this transaction and to be joining forces with Crown Laboratories, which will enable us to broaden our provider network as well as provide us with an expanded portfolio of products. We also believe that the merger provides substantial value for our stockholders. Crown shares our commitment to innovation and scale and will help us accelerate our growth. Scale and product breadth are important factors in the markets in which we compete and, by combining with Crown, we will be able to offer our customers a more compelling range of products and services while, at the same time, benefiting from the combined strength of our collective commercial organizations."

#IPO #ACTION! Looks like it's been quite the ride for these companies in their first few days! Reddit, Inc.'s stock shot up by a whopping 48% on Thursday, right after setting its deal price at the top of its proposed range. Meanwhile, over in Switzerland, Galderma made a grand entrance with a $2.6 billion offering – the largest since ARM Holdings PLC back in September. With SIX (the Swiss Exchange) looking toward a #brighterfuture, it seems like there's a lot of interesting movement happening in the #Europeanmarket. 🚀💼 Did you catch any of this action? #StockMarket #GaldermaIPO #EuropeanMarket #InvestmentOpportunities https://lnkd.in/gtTinU33 More on Galderma here: https://lnkd.in/gtTinU33

Swedish Private Equity Titan EQT Revives IPO Plans for Galderma In a recent report by the Financial Times, it has been revealed that Swedish private equity giant EQT is reigniting its ambitions for an initial public offering of the renowned Swiss skincare entity Galderma. Sources familiar with the matter disclosed that Galderma is gearing up for a potential IPO in Switzerland, slated for the first half of this year, with market pundits speculating a valuation in the vicinity of $20 billion for the subsidiary. The postponement of Galderma's IPO plans was attributed to a crisis of confidence gripping the banking sector. Despite the setback, Galderma successfully amassed approximately $1 billion through a private placement of shares in June. EQT's acquisition of Galderma, formerly a segment of Nestle's Skin Health division, materialized in 2019, orchestrated within an investor consortium featuring the Abu Dhabi Investment Authority and the Canadian pension fund PSP Investments. https://lnkd.in/dsBPxXyd #PrivateEquity #Consumer #IPO #HealthWellness #Skincare

Shares in Incanthera plc shot up 70% in early trading after the developer of skin care products revealed its deal with Switzerland's MARIONNAUD is ramping up faster than anticipated. Its first order has been doubled, while it expects to bank £10m in sales next year and £33m the year after as a result of the tie-up. Stanford Capital Partners Limited sees one of two scenarios playing out. The first is the roll-out across 1,200 Marionnaud outlets, which gets it to £33m in 2026 and £37m the year after. Alternatively, there's take-up not just by Marionnaud but across the AS Watson Group network too, which has 8,000 distributors in China and could generate £90m of revenues in 2027. Incanthera shares jumped 6.5p to 15.75p, while stock in ImmuPharma PLC (AIM:IMM), which owns 10.8% of Incanthera, was up 25% at 2.4p.   More at #Proactive #ProactiveInvestors #AIM #IMM #skincare http://ow.ly/r28Z105nhlh

An interesting talk with JB CEO, Nikhil Chopra. I ask him about growth strategy, talk of a stake sale by PE firm KKR, the trend of multinational pharma firms licensing/selling brands to Indian companies and more in this free to view/listen article and podcast #business #deals #pharmaceuticals #privateequity #PE #India Citeline

"Sanofi will press ahead with plans for a spin-off of its consumer division, which could be one of Europe’s biggest deals this year, adding bankers to work on a sale process and preparations for a public listing expected to value the business at about €20bn." Having been part of the business unit swap between Sanofi and Boehringer Ingelheim in 2016 - 2017 where Sanofi got the consumer healthcare business, it's great to see the ongoing development and the plan to spin-off the consumer business during this high interest rates environment. Let's see how many more spin-offs and de-mergers we're going to see in preparation for a following sale, or IP in the next year(s). #mna #spinoff #demerger #ipo

Alcon sees steady growth

🌐 Exciting company insights in one bundle - Pharma! 🚀 Elevate your sales strategy, stay ahead of competitors, and make informed decisions with valuable insights on mergers, acquisitions, alliances, and partnerships. 📈 Gain a competitive edge with comprehensive competitive intelligence, including SWOT analysis, financial performance, and digital transformation strategies. 🌐 Discover the key factors driving success, future growth prospects, and talent acquisition strategies. 🚀 Join thousands of satisfied clients benefiting from our trusted, actionable, and forward-looking intelligence. Don't miss out on this opportunity to shape your company's future! 👉Explore more here: https://lnkd.in/gzWtWzdy #pharma #pharmaindustry #digitaltransformation #pharmabundle #companyprofile #swot #financialperformance

Thoughts on this? >> Galapagos investor gets board seat; OnKure completes merger with Reneo >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #healthcare #productmarketing